Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

US11890327B2 · kind B2 · utility

Assignee

• CSL BEHRING LENGNAU AG · CH

Inventors

• Sabine Pestel · Biberach, DE
• Elmar Raquet · Rodenbach, DE
• Thomas Weimer · Gladenbach, DE

Key dates

• Filing date: Nov 10, 2017
• Grant date: Feb 6, 2024
• Expiry date: Nov 3, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention pertains to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) for use in the treatment or prophylaxis of a blood coagulation disorder, said treatment or prophylaxis comprising administering the recombinant polypeptide and a Factor VIII protein (FVIII) extravascular to a subject having a blood coagulation disorder, wherein said recombinant polypeptide is capable of binding to said FVIII, and wherein the molar ratio of the recombinant polypeptide to be administered to the FVIII to be administered is higher than 50.